Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Emory and Georgia Memory Net tell committee new Alzheimer's diagnostics and infusions require expanded clinic capacity and state support
Summary
Emory researchers and Georgia Memory Net told the committee that FDA-authorized blood diagnostics (p-tau217) and new antibody infusion treatments can slow Alzheimer's progression but require more memory assessment clinics, infusion capacity and monitoring; presenters said the state program reaches about 6,000 people and receives roughly $7.12 million in state support.
Emory faculty and Georgia Memory Net staff presented to the Committee on Public and Community Health on recent clinical advances and the program's role in early detection and treatment access. Dr. Levy, head of the Emory Alzheimer's Disease Research Center, described new antibody infusions that "remove the amyloid plaques" and reported trial results the presentation summarized as about a 30% slowing in disease progression over the trial period.
Dr. Levy said the treatments are currently intravenous infusions given monthly or every two weeks for roughly 18 months and carry rare but serious risks such as brain bleeding that require specialized monitoring (PET or CSF imaging) and infusion-site capacity. He said a…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
